-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-038 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLX-038 in Fallopian Tube Cancer Drug Details: PLX-038 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: IMG-7289 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details: IMG-7289 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: IMG-7289 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Polycythemia Vera
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Polycythemia Vera Drug Details: IMG-7289 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Essential Thrombocythemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Essential Thrombocythemia Drug Details: IMG-7289 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) Drug Details: IMG-7289 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Myelofibrosis Drug Details: IMG-7289 is under development for the treatment of acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Relapsed Acute Myeloid Leukemia Drug Details: IMG-7289 is under development for the...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...